Please assess the completion status of the following clinical trial:

Trial Title: Aripiprazole and Topiramate on Free-Choice Alcohol Use

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 9.0

Eligibility Criteria:
Inclusion Criteria:~* must be non-treatment seeking for alcohol dependence~* a current DSM-IV-TR diagnosis of alcohol dependence supported by the Structured Clinical Interview for DSM-IV-TR Axis I Disorders Patient Edition (SCID-I/P a minimum of ≥ 35drinks a week for men or ≥ 28 or more drinks a week for women~* must be suitable for outpatient treatment~* able to read English at an eighth grade level, understand their rights as provided by the informed consent, and be willing to sign an informed consent to participate in the study~* be between 21 and 65 years on age (inclusive)~* provide evidence of stable residence in the two months prior to enrollment and no plans to move for the next four months~* provide a verifiable contact person prior to randomization~* be in generally good health as determined by the physical exam, medical history, ECG and laboratory tests~* have a Body Mass Index \>18kg/m2 and \< 33 kg/m2~* if female, must be postmenopausal practicing an effective method of birth control, have negative pregnancy tests at randomization and before the ASAE;~* be willing to be adherent to medication dosing.~Exclusion Criteria:~* clinically significant medical abnormalities (i.e. ECG, hematological assessment, bilirubin \> 150% of the upper limit of normal or ALT or AST elevations \>300% the upper limit of normal, biochemistry including urinalysis, electrolytes,). (Persons with medical conditions that are adequately controlled by their primary care physician will not be excluded.)~* have significant alcohol withdrawal symptoms (clinical institute withdrawal assessment for alcohol revised (CIWA-Ar) \>10~* a history of suicide; history of renal impairment or nephrolithiasis; creatinine clearance of \<60 dl/minute~* pregnant or lactating or not using an adequate form of birth control~* taking other medications that may have an effect on alcohol consumption or are carbonic anhydrase inhibitors~* clinically significant diseases of the gastrointestinal system or active liver disease; subjects compelled to receive treatment to avoid imprisonment or loss of employment~* previously with a history of adverse reaction or hypersensitivity to either Topiramate or aripiprazole~* have a diagnosis of with schizophrenia or bipolar disorder and/or taking antipsychotics and other drugs that inhibit CYP3A4 or CYP2D6 isoenzymes~* history of seizures (e.g. epilepsy)~* patients currently diagnosed with a substance dependence diagnosis other than alcohol or tobacco~* patients who have participated in any clinical trial with an investigational agent within the past 30 days~* individuals with a reasonable expectation of being institutionalized during the course of the trial or pending legal charges~* pregnant or nursing women.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Double Placebo (Type: PLACEBO_COMPARATOR): Placebo, Placebo
- Aripiprazole 15, Placebo (Type: EXPERIMENTAL): 15 mg Aripiprazole, Placebo
- Aripiprazole 7.5, Placebo (Type: EXPERIMENTAL): Aripiprazole 7.5 mg daily plus Placebo daily
- Topiramate 100mg, Placebo (Type: EXPERIMENTAL): Topiramate 100 mg daily plus Placebo daily
- Topiramate 200, Placebo (Type: EXPERIMENTAL): Topiramate 200 mg daily plus Placebo daily
- Topiramate 100, Aripiprazole 5 (Type: EXPERIMENTAL): Topiramate 100 daily plus, Aripiprazole 5mg daily
- Topiramate 200, Aripiprazole 15 (Type: EXPERIMENTAL): Topiramate 200 mg daily plus Aripiprazole 15mg daily
- Topiramate 100, Aripiprazole 7.5 (Type: EXPERIMENTAL): Topiramate 100 mg daily, Aripiprazole 7.5 mg daily
- Topiramate 200, Aripiprazole 7.5mg (Type: EXPERIMENTAL): Topiramate 200 mg daily plus Aripiprazole 7.5mg daily

Based on this trial design, predict the completion outcome and termination type (if applicable).